Disclosure. Objectives: Technician. Objectives: Pharmacist. Diagnostic and Statistical Manual (DSM-V) The Face of Mental Illness 7/25/2015

Size: px
Start display at page:

Download "Disclosure. Objectives: Technician. Objectives: Pharmacist. Diagnostic and Statistical Manual (DSM-V) The Face of Mental Illness 7/25/2015"

Transcription

1 49th Annual Meeting Psychiatry for the Non-Psychiatry Specialist Jacintha Cauffield, PharmD, BCPS, CDE Associate Professor of Pharmacy Practice Lloyd L. Gregory School of Pharmacy Palm Beach Atlantic University Disclosure I do not have a vested interest in or affiliation with any corporate organization offering financial support or grant monies for this continuing education activity, or any affiliation with an organization whose philosophy could potentially bias my presentation OWNING CHANGE: Taking Charge of Your Profession Objectives: Pharmacist Objectives: Technician Differentiate amongst common psychiatric conditions Determine medication treatment for the various discussed psychiatric conditions Prevent adverse effects and drug interactions related to treatment Explore the psychosocial and societal challenges and misconceptions with psychiatric disorders and their treatment Differentiate amongst common psychiatric conditions Identify common medications used to treat the psychiatric disorders discussed Recognize potential adverse effects and drug interactions related to treatment Explore the psychosocial and societal challenges and misconceptions with psychiatric disorders and their treatment The Face of Mental Illness Diagnostic and Statistical Manual (DSM-V) Standard classification of mental disorders Based upon signs and symptoms Diagnostic criteria developed to increase reliability No reliable objective methods for psychiatric diagnosis Symptoms + Severity (impairment of normal function) 1

2 Commonly Seen Psychiatric Conditions in Adults Attention Deficit Hyperactivity Disorder (ADHD) Anxiety* Generalized Anxiety Disorder (GAD) Panic Disorder Agoraphobia Social Anxiety Disorder (SAD) Bipolar Disorder Depression Schizophrenia *Obsessive Compulsive Disorder (OCD) and Posttraumatic Stress Disorder (PTSD) are now classified separate from Anxiety Disorders Schizophrenia: Diagnosis NOT a split personality Major symptoms (> 2 for at least 1 month) Delusions Hallucinations Disorganized speech Grossly disorganized or catatonic behavior Negative symptoms Must have at least one of these three symptoms Depression Diagnosis: DSM-V Depressed mood Anhedonia Significant weight loss or gain Change in sleep habits Psychomotor agitation or retardation Fatigue or loss of energy Feelings of worthlessness/inappropriate guilt Decreased ability to think/concentrate; indecisive Recurrent thoughts of death/suicidal ideation Bipolar Disorder Elevated mood AND ed goal directed activity Mania Hypomania Diagnosis Bipolar Disorder Type I Bipolar Disorder Type II Major Depression? Not necessarily Yes-Hallmark Duration >1 week > 4 days Severity Marked impairment Hospitalization Psychosis possible Impairment, if present, is mild Noticed by others Identification Hallmark Can be missed What Is an Elevated Mood? 3 symptoms (elation) or 4 symptoms (irritability): Decreased need for sleep Distractibility Excessive involvement in high risk pleasurable activity Flight of ideas Grandiosity Increase in energy, goal-directed activity or psychomotor agitation Pressured speech Attention Deficit Hyperactivity Disorder (ADHD) Inattentive Hyperactive/Impulsive Careless mistakes/unable to give close Fidgets and squirms attention Leaves seat when inappropriate Difficulty keeping attention Runs about or climbs when Doesn t listen inappropriate Fails to finish tasks (loses focus) Unable to play quietly Difficulty organizing On the go / Driven by a motor Avoids tasks that require mental effort Talks excessively over long periods of time Blurts out answers before question Loses things often completed Easily distracted Difficulty waiting turns Forgetful in daily tasks Interrupts or intrudes on others Combined: symptoms of both inattentive and hyperactive/impulsive 2 or more settings Before age 12 For at least 6 months 2

3 Anxiety Disorders Anxiety Disorders How do I know if it s pathological? Excessiveness Intensity Duration (chronicity) Impairment Significant physical element Underdiagnosed Waxes and wanes Low remission rate Worsens prognosis of comorbid psychiatric conditions Uncontrollable worry about several areas Generalized Anxiety Disorder Uncued/ Spontaneous Panic Disorder Symptom Focus Fear of exposed places Agoraphobia Intermittent panic/anxiety symptoms and avoidance Fear of social scrutiny Social Anxiety Disorder Discrete object or situation Specific Phobia How does bipolar disorder differ from depression? A. Decreased sleep B. Elevated mood C. Loss of appetite D. Decreased concentration Correct Diagnosis Leads to Effective Treatment Matching Medications to Conditions Medication Anxiety Bipolar Disorder Depression Schizophrenia Anticonvulsants Adjunct Yes No Adjunct Antidepressants Yes? Yes No Antipsychotics Adjunct Yes Adjunct Yes Benzodiazepines Yes No No No Lithium No Yes Adjunct No ADHD Stimulants (amphetamine salts, dextroamphetamine, dexmethylphenidate, lisdexamfetamine, methylphenidate) Atomoxetine Clonidine Guanfacine Which medications am I most likely to see: 2013 IMS Data Class Medication Antidepressants Bupropion (SR, L) Citalopram Desvenlafaxine Duloxetine Escitalopram Antipsychotics Aripiprazole Olanzapine Benzodiazepines Alprazolam Diazepam Lorazepam Stimulants Other Amphetamine salts (immediate and ER) Lisdexamfetamine Methylphenidate (generic, Concerta ER) Buspirone Hydroxyzine Paroxetine Sertraline Trazodone Venlafaxine ER Quetiapine 3

4 Treatment Conundrums: Antipsychotics in Schizophrenia SGAs: Other Indications First generation Antipsychotics (FGA) (Typical) (e.g. chlorpromazine, haloperidol) More uniform class low potency anticholinergia high potency More movement disorders (EPS) EPS is a class effect Hyperprolactinemia vs. Second Generation Antipsychotics (SGA) (Atypical) (e.g. aripiprazole, olanzapine) More effective against negative symptoms? More diverse class Differing side effect profiles Metabolic syndrome Not devoid of movement disorders Aripiprazole Clozapine Lurasidone Olanzapine Quetiapine Ziprasidone Anxiety (Adjunct-SAD) (SAD; Adjunct-GAD) (GAD, SAD) (Adjunct-GAD, SAD) Depression (Adjunct) Bipolar DO (Mania) Bipolar DO (Depression) Not effective (likely) (with fluoxetine) ER only (- Monotherapy) (with fluoxetine) Addressing FGA ADRs SGAs: Metabolic Syndrome Switch agents if possible Acute Dystonias: treat/prophylax with anticholinergic Benztropine Parkinsonian syndromes: anticholinergic Akathisia: Lipophilic beta blocker (propranolol) Tardive dyskinesia: no known treatment Weight Gain Clozapine = olanzapine (26.3%) Low potency FGAs Quetiapine (17%) (9%)=paliperidone High potency FGAs Lurasidone Ziprasidone (5.8%) Aripiprazole (4.9%) *FDA considers >7% clinically significant Worst Least Glucose Intolerance Clozapine=olanzapine Quetiapine=risperidone=paliperidone Lurasidone > Ziprasidone=aripiprazole ADA: consider a change in antipsychotics if >5% weight gain SGAs: Selected ADRs ADR High Low Akathisia Aripiprazole, lurasidone Quetiapine Agranulocytosis Clozapine ---- EPS (>6 mg/day) Clozapine, quetiapine Hyperprolactinemia ---- QTc prolongation Ziprasidone (aripiprazole, clozapine, olanzapine, risperidone, quetiapine) * ---- Sedation Clozapine, olanzapine, Aripiprazole quetiapine Seizures Clozapine ---- SGAs can be used to treat: (Choose all that apply!) A. ADHD B. Depression C. Mania D. Schizophrenia * 4

5 Antidepressants in Depression Antidepressant Classes No definitive first-line agent Side effect profile Previous response Family member response Class Serotonin Selective Reuptake Inhibitors (SSRIs) Serotonin Norepinephrine Reuptake Inhibitor (SNRIs) Mixed Serotonergic Activity Other Agents Citalopram, escitalopram, fluoxetine, paroxetine, sertraline Desvenlafaxine, duloxetine, levomilnacipran, venlafaxine Vortioxetine, vilazodone Bupropion, mirtazapine Antidepressant-Patient Matches Bipolar Depression: Antidepressants Symptom (that is present) Weight loss Weight gain Insomnia Hypersomnia Suicidal ideation Antidepressant (counteract symptom) Mirtazapine, paroxetine, TCAs Bupropion, duloxetine, SSRIs (except paroxetine), venlafaxine Mirtazapine, TCAs, paroxetine, trazodone Bupropion, duloxetine, fluoxetine, sertraline, vilazodone NOT TCAs, avoid bupropion; use SSRIs Neuropathic pain Duloxetine, TCAs (amtitriptyline (?), desipramine, nortriptyline) Sexual dysfunction Bupropion, mirtazapine, nefazodone, vilazodone? Pregnancy, sertraline, bupropion? Evidence for efficacy weak Can cause a switch to mania (TCAs, venlafaxine) Monotherapy Bipolar I Bupropion, fluoxetine, paroxetine: little to no switching Use: h/o positive response Relapses off of antidepressant Bipolar II? Bipolar Depression: Alternatives Lamotrigine (not acutely) Lurasidone Olanzapine + fluoxetine Other SSRI/SGA combinations? Quetiapine Lithium (partial relief) Pharmacotherapy: Anxiety DO Often a balancing act Antidepressants (SSRIs) Benzodiazepines Cornerstone of pharmacotherapy Short term use Treat cognitive and behavioral Treat somatic and autonomic symptoms symptoms Effective across anxiety DO Effective only for GAD, panic DO; spectrum avoid in SAD Take 2-4 weeks to manifest Immediate relief benefits Can initially worsen symptoms Symptom relief Buspirone takes 2-4 weeks of scheduled dosing for relief 5

6 Pharmacotherapy: PTSD and OCD Benzodiazepines ineffective PTSD: therapy tailored to symptoms SSRIs central Additional treatments added based upon symptoms OCD: antidepressant with serotonergic activity necessary SSRIs, clomipramine Adjunctive antipsychotics Medication Interactions Pharmacokinetic Pharmacodynamic Substrate Psychiatric Medication Interactions: Pharmacokinetic 1A2 2C19 2D6 3A4 Caffeine Clozapine Olanzapine Ramelteon Citalopram Diazepam Escitalopram Sertraline Vilazodone Inhibitor Fluvoxamine Amitriptyline Fluvoxamine Imipramine Inducer Carbamazepine Smoking Barbiturates St. John s Wort Aripiprazole Atomoxetine Some FGAs Paliperidone SSRIs Trazodone TCAs Venlafaxine Vortioxetine Paroxetine Benzodiazepines Buspirone Desvenlafaxine Guanfacine Levomilnacipran Lurasidone Quetiapine TCAs (some) Vilazodone Z drugs Fluvoxamine Nefazodone Barbiturates Carbamazepine St. John s Wort Additional Pharmacokinetic DDIs Valproic acid (VPA) and Lamotrigine (LTG) VPA inhibits LTG metabolism through UGT LTG concentrations Stevens Johnson Syndrome Low doses of VPA ( mg/day) Cut LTG by half A physician wishes to add an antipsychotic to a patient s regimen. He is taking fluoxetine concomitantly. Which is best? A. Aripiprazole B. Haloperidol C. Quetiapine D. Pharmacodynamic: Serotonin Syndrome What is it? Altered Mental Status Neuromuscular Hyperactivity Autonomic Instability Hunter s criteria Spontaneous clonus Agents Dextromethorphan Linezolid Monoamine Oxidase Inhibitors Opioids (fentanyl, meperidine) SNRIs SSRIs Stimulants Tramadol Triptans? Inducible clonus + agitation or diaphoresis Ocular clonus + agitation or diaphoresis Tremor AND hyperreflexia ONLY Hypertonia AND temp > 38 o C AND ocular or inducible clonus 6

7 Pharmacodynamic: QTc Prolongation* and Torsade des Pointes (TdP) 92%: additional risk factor (e.g. overdose, drugdrug interaction) Known TdP Risk Possible TdP Risk Conditional TdP Risk Chlorpromazine Citalopram Escitalopram Haloperidol Mesoridazine (d/c ed) Thioridazine Aripiprazole Atomoxetine Clozapine Iloperidone Lithium Mirtazapine Olanzapine Paliperidone Quetiapine TCAs (most) Venlafaxine Ziprasidone *QTC > msec; Amitriptyline Doxepin Paroxetine Sertraline Living with a Psychiatric Condition (Mental Illness) Which statement is true with regard to people who have psychiatric conditions? A. They can t live productive lives. B. Self- advocacy is difficult when they are sick. C. Pharmacotherapy is usually adequate to achieve and maintain remission. D. They are prone to violence and are commonly a danger to others. Mental Illness and the Criminal Justice System 2012: Patients with severe mental illness in jail: 356,268 Patients in psychiatric hospitals: 35,000 Rate of violent crime low Substance Abuse Crimes of survival accessed 6/26/2015; Law Human Behav 2014;38:439. Barriers to Treatment Can t advocate for self Patients unable to articulate symptoms Lack of energy Inability to concentrate Inability to organize Lack of insight Communication blocks Aren t We Overmedicating Patients? Medication is only part of the solution Medication improves patient ability to participate in nonpharmacologic measures Psychotherapy and psychoeducation are essential Better long term outomes Treat early to prevent complications Consider step down therapy 7

8 Supporting the Patient who has a Psychiatric Condition: Resources Unusual behavior may be a symptom Offer support National Alliance on Mental Illness National Institute of Mental Health College of Psychiatric and Neurologic Pharmacists 8

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral

More information

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder

More information

Index. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers

Index. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic

More information

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.

More information

PSYCHIATRY DRUG ALERTS, VOLUME XXVIII, 2014 INDEX

PSYCHIATRY DRUG ALERTS, VOLUME XXVIII, 2014 INDEX A acamprosate ADHD Generic Methylphenidate Equivalence, 84 Methylphenidate in Pregnancy, 9 Stimulants in Pregnancy, 50 adverse effects Antidepressant-Induced Jitteriness, 94 Antidepressants and Sexual

More information

Psychiatry in Primary Care: What is the Role of Pharmacist?

Psychiatry in Primary Care: What is the Role of Pharmacist? Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure

More information

CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX

CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release

More information

CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XV, 2013 INDEX

CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XV, 2013 INDEX A acceptance and commitment therapy Posttraumatic Stress, 69 ADHD Adjunctive Fatty Acids, 5 Adjunctive Guanfacine Pharmacokinetics, 27 Amantadine, 21 Atomoxetine, 23 Cancer Risk, 31 CBT for Comorbid Anxiety,

More information

ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY

ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100

More information

Anxiety Disorders.

Anxiety Disorders. Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner

More information

Introduction to Drug Treatment

Introduction to Drug Treatment Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical

More information

Riding the Waves: Tools for the Management of Bipolar Disorder

Riding the Waves: Tools for the Management of Bipolar Disorder Riding the Waves: Tools for the Management of Bipolar Disorder Jacintha S. Cauffield, Pharm.D., BCPS, CDE Associate Professor of Pharmacy Practice Palm Beach Atlantic University Lloyd L. Gregory School

More information

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17

More information

Schedule FDA & literature based indications

Schedule FDA & literature based indications Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for

More information

Announcements. The final Aplia gauntlet: Final Exam is May 14, 3:30 pm Still more experiments going up daily! Enhanced Grade-query Tool+

Announcements. The final Aplia gauntlet: Final Exam is May 14, 3:30 pm Still more experiments going up daily! Enhanced Grade-query Tool+ The final Aplia gauntlet: Announcements Chapter 12 Aplia due tonight Chapter 13 Aplia due Wednesday Final Exam is May 14, 3:30 pm Still more experiments going up daily! Enhanced Grade-query Tool+ Now includes

More information

Objectives. DSM-V Changes: Elimination of Multiaxial Diagnostic System

Objectives. DSM-V Changes: Elimination of Multiaxial Diagnostic System Conflicts of Interest I have no conflicts to disclose. 2014 Updates to the Updates in Pharmacotherapy Webinar Psychiatry Updates for Pharmacotherapy Specialists Jacintha S. Cauffield, Pharm.D., BCPS Associate

More information

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines

More information

Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment

Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,

More information

Medications and Children Disorders

Medications and Children Disorders Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for

More information

Mood Disorders.

Mood Disorders. Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner

More information

PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer

PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally

More information

Psychotropic Medication Use in Dementia

Psychotropic Medication Use in Dementia Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,

More information

Mentoring Session: Participant Cases

Mentoring Session: Participant Cases Handout for the Neuroscience Education Institute (NEI) online activity: Mentoring Session: Participant Cases The Case: 55-year-old patient with depression and anxiety The Question: What to do when antidepressants

More information

48 th Annual Meeting. Clinical Pearls: Depression, Insomnia and Bipolar Disorder DSM-5. Disclosure. Depression. Patient Case. Objectives 7/19/2014

48 th Annual Meeting. Clinical Pearls: Depression, Insomnia and Bipolar Disorder DSM-5. Disclosure. Depression. Patient Case. Objectives 7/19/2014 48 th Annual Meeting Clinical Pearls: Depression, Insomnia and Bipolar Disorder DSM-5 Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Published in 2013 Most published treatment guidelines

More information

MEDICATION ALGORITHM FOR ANXIETY DISORDERS

MEDICATION ALGORITHM FOR ANXIETY DISORDERS Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON

More information

Mental illness A Broad Overview. Dr H Pathmanandam March 2017

Mental illness A Broad Overview. Dr H Pathmanandam March 2017 Mental illness A Broad Overview Dr H Pathmanandam March 2017 Introduction Mental disorders are common in primary and secondary care Many are not recognised and not treated Some receive unnecessary or inappropriate

More information

Treatment-resistant depression in primary care

Treatment-resistant depression in primary care Treatment-resistant depression in primary care Interprofessional CME, October 2017 Brian J. Mickey, MD, PhD Associate Professor School of Medicine Department of Psychiatry Disclosures Speakers bureau:

More information

Psychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis

Psychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis Psychiatric Illness In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis 12,000,000 children infants through 18 y/o nation wide 5,000,000 suffer severely Serious

More information

Depression & Anxiety in Adolescents

Depression & Anxiety in Adolescents Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with

More information

Treatment Options for Bipolar Disorder Contents

Treatment Options for Bipolar Disorder Contents Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8

More information

New Patient Questionnaire

New Patient Questionnaire 4 Embarcadero Center, Suite 1400, San Francisco, CA 94111 (415) 926-7774 phone; (415) 591-7760 office@sanfranciscopsych.com New Patient Questionnaire Thank you for trusting San Francisco Psychiatry with

More information

PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA

PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment

More information

Medically Accepted Indications for Pediatric Use of Psychotropic Medications by

Medically Accepted Indications for Pediatric Use of Psychotropic Medications by Key: White Background: Medically Accepted Indication Yellow Backgroun: Medically Accepted Indication Status Not Ascertained Orange Background: Pediatric Indication cited, but not supported Red Background:

More information

A Basic Approach to Mood and Anxiety Disorders in the Elderly

A Basic Approach to Mood and Anxiety Disorders in the Elderly A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict

More information

Depression. University of Illinois at Chicago College of Nursing

Depression. University of Illinois at Chicago College of Nursing Depression University of Illinois at Chicago College of Nursing 1 Learning Objectives Upon completion of this session, participants will be better able to: 1. Recognize depression, its symptoms and behaviors

More information

Manual of Clinical Psychopharmacology

Manual of Clinical Psychopharmacology Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School

More information

Class: Treatment with Medication:

Class: Treatment with Medication: Class: As we have not finished all the material covering disorders, I wanted to give you and overview of some disorders we have not had a chance to discuss. I feel you are well prepared in different types

More information

Things You Might Not Know About Psychotropic Medications But Wish You Did

Things You Might Not Know About Psychotropic Medications But Wish You Did Things You Might Not Know About Psychotropic Medications But Wish You Did John E. Dunne, MD December 3, 2016 PAL Conference Conflicts of Interest None to report I am employed by Seattle Children s and

More information

Mental Health DNA Insight WHITE PAPER

Mental Health DNA Insight WHITE PAPER Mental Health DNA Insight WHITE PAPER JULY 2016 Mental Health DNA Insight / White Paper Mental Health DNA Insight Pathway Genomics Mental Health DNA Insight test is aimed to help psychiatrists, neurologists,

More information

Eligible Beneficiaries

Eligible Beneficiaries Therapeutic Class: Behavioral Health Medications for Adults Clinical Edit Number Long Description 4110 (May change) Quantity limit edit that is applied to atypical antipsychotics for claims identified

More information

Guide to Psychiatric Medications for Children and Adolescents

Guide to Psychiatric Medications for Children and Adolescents Guide to Psychiatric Medications for Children and Adolescents by Glenn S. Hirsch, M.D. The following guide includes most of the medications used to treat child and adolescent mental disorders. It lists

More information

4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies

4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies Child & Adolescent Behavioral Medicine & Medication Therapies Brian J Cowles, PharmD Associate Professor of Pharmacy Practice Albany College of Pharmacy & Health Sciences; Vermont Campus Behavioral Medicine

More information

Affective or Mood Disorders. Dr. Alia Shatanawi March 12, 2018

Affective or Mood Disorders. Dr. Alia Shatanawi March 12, 2018 Affective or Mood Disorders Dr. Alia Shatanawi March 12, 2018 Affective or Mood Disorders Reactive Depression. Secondary: Medical Neurological Drugs Major (Endogenous) Depression = Unipolar: Depressed

More information

Pediatric Psychopharmacology

Pediatric Psychopharmacology Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders

More information

SAMPLE REPORT MENTAL HEALTH DNA INSIGHT LABORATORY INFO. Protected Health Information. SSRIs. TCAs. Other Antidepressants

SAMPLE REPORT MENTAL HEALTH DNA INSIGHT LABORATORY INFO. Protected Health Information. SSRIs. TCAs. Other Antidepressants Test Results Reviewed & Approved by: Laboratory Director, Nilesh Dharajiya,.D. ENTAL HEALTH DNA INSIGHT PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROFESSIONAL Glenn Braunstein.D.

More information

Practice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder,

Practice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder, Practice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder, Journal of the Academy of Child and Adolescent Psychiatry, 1997 Primary Authors: Jon McClellan MD

More information

Mixing and Matching: Layering Medications as Family Physicians

Mixing and Matching: Layering Medications as Family Physicians Mixing and Matching: Layering Medications as Family Physicians Family Medicine Forum Vancouver, B.C. November 9-12, 2016. Jon Davine, CCFP, FRCP(C) McMaster University Objectives Discuss different examples

More information

Updates in Therapeutics 2015: Ambulatory Care Pharmacy Preparatory Review and Recertification Course Psychiatric Disorders William A.

Updates in Therapeutics 2015: Ambulatory Care Pharmacy Preparatory Review and Recertification Course Psychiatric Disorders William A. Updates in Therapeutics 2015: Ambulatory Care Pharmacy Preparatory Review and Recertification Course Psychiatric Disorders William A. Kehoe, Pharm.D., MA, FCCP, BCPS Professor of Pharmacy Practice University

More information

Disclosure Information

Disclosure Information Disclosure Information I have no financial relationships to disclose. I will discuss the off label use of several depression and anxiety medications in pediatric population Pediatric Depression & Anxiety

More information

Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence

Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole

More information

Antipsychotic Use in the Elderly

Antipsychotic Use in the Elderly Antipsychotic Use in the Elderly Presented by: Fatima M. Ali, PharmD, RPh, BCPS Clinical Consultant Pharmacist MediSystem Pharmacy, Kingston Originally Prepared by: Nicole Tisi BScPhm, RPh ACPR Disclosure

More information

Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School

Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School of Psychology, Fuller Theological Seminary Medical

More information

Clinical Guideline for the Management of Bipolar Disorder in Adults

Clinical Guideline for the Management of Bipolar Disorder in Adults Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:

More information

Presenter Disclosure. Objectives 6/5/2017. Depression, Anxiety, PTSD: A Focus on Pharmacotherapy

Presenter Disclosure. Objectives 6/5/2017. Depression, Anxiety, PTSD: A Focus on Pharmacotherapy Depression, Anxiety, PTSD: A Focus on Pharmacotherapy Robert L Page II, Pharm.D., MSPH, FHFSA, FCCP, FAHA Professor of Clinical Pharmacy Clinical Specialist, Division of Cardiology University of Colorado

More information

Depression in Late Life

Depression in Late Life Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression

More information

PSYCHIATRY INTAKE FORM

PSYCHIATRY INTAKE FORM Please complete all information on this form. PSYCHIATRY INTAKE FORM Name Date Date of Birth Primary Care Physician Current Therapist/Counselor What are the problem(s) for which you are seeking help? 1.

More information

Psychiatric Medication Guide

Psychiatric Medication Guide Psychiatric Medication Guide F O R : N E O N P R I M A R Y H E A L T H C A R E P R O V I D E R S B Y : M I C H E L L E R O M E R O, D O M A Y, 2 0 1 3 Anti-depressants TCA s & MAOI s (Tricyclic Antidepressants

More information

Disclosure Statement. A Rational Approach to Psychopharmacology. Goals 10/28/2013

Disclosure Statement. A Rational Approach to Psychopharmacology. Goals 10/28/2013 A Rational Approach to Psychopharmacology Disclosure Statement Full time employed physician with MaineGeneral Medical Center in Waterville and Augusta No conflicts of interest to disclose Goals Promote

More information

Augmentation and Combination Strategies in Antidepressants treatment of Depression

Augmentation and Combination Strategies in Antidepressants treatment of Depression Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported

More information

Prevalence of Comorbidity and Pattern Drug Use among Children with Attention-deficit hyperactivity disorder: A Single Center in Thailand

Prevalence of Comorbidity and Pattern Drug Use among Children with Attention-deficit hyperactivity disorder: A Single Center in Thailand The 25th Federation Of Asian Pharmaceutical Association (FAPA) Congress 2014 Kota Kinabalu, Sabah, Malaysia 9th - 12th October, 2014 Prevalence of Comorbidity and Pattern Drug Use among Children with Attention-deficit

More information

Antidepressants. Dr Malek Zihlif

Antidepressants. Dr Malek Zihlif Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric

More information

Child & Adolescent Psychiatry (a brief overview)

Child & Adolescent Psychiatry (a brief overview) Child & Adolescent Psychiatry (a brief overview) Lance Feldman, MD, FAPA, MBA, BSN Vice Chair Clinical Affairs, Department of Psychiatry Affiliate Clinical Assistant Professor, University of South Carolina

More information

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free

More information

Antidepressant Selection in Primary Care

Antidepressant Selection in Primary Care Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize

More information

Presentation is Being Recorded

Presentation is Being Recorded Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please

More information

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please

More information

Strategies for Diagnosing and Treating Depressive Disorders in Primary Care

Strategies for Diagnosing and Treating Depressive Disorders in Primary Care Strategies for Diagnosing and Treating Depressive Disorders in Primary Care David Katerndahl, MD, MA University of Texas Health Science Center San Antonio, Texas Speaker Disclosure Dr. Katerndahl has disclosed

More information

PL CE LIVE February 2011 Forum

PL CE LIVE February 2011 Forum February 2011 PL CE LIVE Kristin W. Weitzel, Pharm.D., CDE, FAPhA Associate Editor and Director of Editorial Projects Pharmacist s Letter/Prescriber s Letter Atypical Antipsychotics Atypical Antipsychotics

More information

COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications*

COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* Bupropion (Wellbutrin) Start: IR-100 mg bid X 4d then to 100 mg tid; SR-150

More information

Anti-Depressant Medications

Anti-Depressant Medications Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change

More information

Happy Daisy Ltd. New Client intake Form. What are the issues for which you are seeking care?

Happy Daisy Ltd. New Client intake Form. What are the issues for which you are seeking care? Happy Daisy Ltd. New Client intake Form Name Date Preferred name Pronouns Referred by Date of birth Age Race What are the issues for which you are seeking care? 1. 2. 3. Please check of any of the symptoms

More information

Kelly Godecke, MD Department of Psychiatry University of Utah

Kelly Godecke, MD Department of Psychiatry University of Utah Kelly Godecke, MD Department of Psychiatry University of Utah Epidemiology and Impact -module 2 session 1 overview of mood disorders Diagnostic Criteria of Bipolar Disorders Medications Used in Bipolar

More information

Jolene R. Bostwick, PharmD, BCPS, BCPP Clinical Associate Professor Associate Chair, Department of Clinical Pharmacy University of Michigan College

Jolene R. Bostwick, PharmD, BCPS, BCPP Clinical Associate Professor Associate Chair, Department of Clinical Pharmacy University of Michigan College Jolene R. Bostwick, PharmD, BCPS, BCPP Clinical Associate Professor Associate Chair, Department of Clinical Pharmacy University of Michigan College of Pharmacy Clinical Pharmacist in Psychiatry University

More information

Study Guidelines for Quiz #1

Study Guidelines for Quiz #1 Annex to Section J Page 1 Study Guidelines for Quiz #1 Theory and Principles of Psychopharmacology, Classifications and Neurotransmitters, Anxiolytics/Antianxiety/Minor Tranquilizers, Stimulants, Nursing

More information

Are All Older Adults Depressed? Common Mental Health Disorders in Older Adults

Are All Older Adults Depressed? Common Mental Health Disorders in Older Adults Are All Older Adults Depressed? Common Mental Health Disorders in Older Adults Cherie Simpson, PhD, APRN, CNS-BC Myth vs Fact All old people get depressed. Depression in late life is more enduring and

More information

Antipsychotics. Something Old, Something New, Something Used to Treat the Blues

Antipsychotics. Something Old, Something New, Something Used to Treat the Blues Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer

More information

Use of Psychotropic Medications in Older Adults with Dementia!

Use of Psychotropic Medications in Older Adults with Dementia! Use of Psychotropic Medications in Older Adults with Dementia! Deepa Pattani, PharmD, RPh Owner: PrevInteract Health Deepa.Pattani@PrevInteract.com 972-372-9775 About Me Deepa Pattani, PharmD, RPh with

More information

Change Your Brain, Change Your Life. The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness

Change Your Brain, Change Your Life. The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness Change Your Brain, Change Your Life The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness Daniel G Amen Three Rivers Press New York Appendix Medication 1.

More information

Adverse events of common psychiatric medications: an umbrella review

Adverse events of common psychiatric medications: an umbrella review Adverse events of common psychiatric medications: an umbrella review Katrina Bartellas, 1 Thomas Bajorek 1 Sarah Stockton, 1 Stefan Leucht, 2 Andrea Cipriani, 1 Seena Fazel 1 1 Department of Psychiatry,

More information

Treatment of Anxiety (without benzos)

Treatment of Anxiety (without benzos) Treatment of Anxiety (without benzos) Alison C. Lynch MD MS Clinical Professor Departments of Psychiatry and Family Medicine University of Iowa Health Care None Disclosures Overview/objectives Review common

More information

Psychobiology Handout

Psychobiology Handout Nsg 85A / Psychiatric Page 1 of 7 Psychobiology Handout STRUCTURE AND FUNCTION OF THE BRAIN Psychiatric illness and the treatment of psychiatric illness alter brain functioning. Some examples of this are

More information

Antidepressant Selection in Primary Care

Antidepressant Selection in Primary Care Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants.

More information

Paediatric Psychopharmacology. Dr Jalpa Bhuta. MD, DNB, MRCPsych (UK).

Paediatric Psychopharmacology. Dr Jalpa Bhuta. MD, DNB, MRCPsych (UK). Paediatric Psychopharmacology. Dr Jalpa Bhuta. MD, DNB, MRCPsych (UK). Childhood pharmacokinetics Children have greater hepatic capacity More glomerular filtration Less fatty tissue Less ability to store

More information

GUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS

GUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS City and County of San Francisco Mayor Gavin Newsom Department of Public Health Community Behavioral Health Services 1380 Howard Street 5 th Floor San Francisco, CA 94103 GUIDELINES FOR THE USE OF PSYCHOACTIVE

More information

John E. Kraus, M.D., Ph.D.

John E. Kraus, M.D., Ph.D. John E. Kraus, M.D., Ph.D. Chief, Adult Psychiatry, Dorothea Dix Hospital, Raleigh, NC Assistant Professor/Associate Director of Residency Training, Dept. of Psychiatry, UNC Hospitals, Chapel Hill, NC

More information

HEDIS BEHAVIORAL HEALTH RESOURCE GUIDE

HEDIS BEHAVIORAL HEALTH RESOURCE GUIDE HEDIS BEHAVIORAL HEALTH RESOURCE GUIDE What is HEDIS? 3 HEDIS Reference Guide for Behavioral Health 4 Behavioral Health HEDIS Measures 13 WHAT IS HEDIS? HEDIS (Healthcare Effectiveness Data and Information

More information

Pharmacists in Medication Adherence in Psychiatric Patients

Pharmacists in Medication Adherence in Psychiatric Patients Pharmacists in Medication Adherence in Psychiatric Patients Mamta Parikh, PharmD, BCPS, BCPP Assistant Professor, Clinical and Administrative Sciences Notre Dame of Maryland University School of Pharmacy

More information

Drugs for Emotional and Mood Disorders Chapter 16

Drugs for Emotional and Mood Disorders Chapter 16 Drugs for Emotional and Mood Disorders Chapter 16 NCLEX-RN Review Question 1 Choices Please note Question #1 at the end of Ch 16 pg 202 & Key pg 805 answer is #4 1. Psychomotor symptoms 2. Tachycardia,

More information

Bipolar Disorder 4/6/2014. Bipolar Disorder. Symptoms of Depression. Mania. Depression

Bipolar Disorder 4/6/2014. Bipolar Disorder. Symptoms of Depression. Mania. Depression Bipolar Disorder J. H. Atkinson, M.D. Professor of Psychiatry HIV Neurobehavioral Research Programs University of California, San Diego KETHEA, Athens Slides courtesy of John Kelsoe, M.D. Bipolar Disorder

More information

Jonathan Haverkampf BIPOLAR DISORDR BIPOLAR DISORDER. Dr. Jonathan Haverkampf, M.D.

Jonathan Haverkampf BIPOLAR DISORDR BIPOLAR DISORDER. Dr. Jonathan Haverkampf, M.D. BIPOLAR DISORDER Dr., M.D. Abstract - Bipolar disorder is a condition affecting an individual s affective states (mood). The different flavors of bipolar disorder have in common that there are alterations

More information

NorthSTAR. Pharmacy Manual

NorthSTAR. Pharmacy Manual NorthSTAR Pharmacy Manual Revised October, 2008 Table of I. Introduction II. III. IV. Antidepressants New Generation Antipsychotic Medications Mood Stabilizers V. ADHD Medications VI. Anxiolytics and Sedative-Hypnotics

More information

Drugs, Society and Behavior

Drugs, Society and Behavior SOCI 270 Drugs, Society and Behavior Spring 2016 Professor Kurt Reymers, Ph.D. Chapter 8 Medication for Mental Disorders 1. Mental Disorders: a. The Medical Model Model: symptoms diagnosis determination

More information

Ohio Psychotropic Medication Quality Improvement Collaborative. Minds Matter. Toolkit. for You and Your Family. This is the property of

Ohio Psychotropic Medication Quality Improvement Collaborative. Minds Matter. Toolkit. for You and Your Family. This is the property of Minds Matter Ohio Psychotropic Medication Quality Improvement Collaborative Minds Matter Toolkit for You and Your Family This is the property of About Minds Matter Minds Matter is a project to help teens,

More information

Objectives. Mental Health Info MEDICATION USE IN ASSISTED LIVING FACILITIES FOR MENTAL HEALTH ISSUES 11/12/2018

Objectives. Mental Health Info MEDICATION USE IN ASSISTED LIVING FACILITIES FOR MENTAL HEALTH ISSUES 11/12/2018 MEDICATION USE IN ASSISTED LIVING FACILITIES FOR MENTAL HEALTH ISSUES Holly Altenberger, PharmD, RPh Director of Pharmacy O Connell Pharmacy holly@oconnellpharmacy.com Objectives At the conclusion of the

More information

Pharmacological Treatment of Anxiety & Depressive Disorders

Pharmacological Treatment of Anxiety & Depressive Disorders Pharmacological Treatment of Anxiety & Depressive Disorders Dr Gary Jackson (MB BCh FRCPsych) Consultant Psychiatrist The Priory Hospital Chelmsford Wellesley Hospital Southend-on-Sea Medical Secretary:

More information

PSYCHIATRIC MANAGEMENT IN PRIMARY CARE. Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust

PSYCHIATRIC MANAGEMENT IN PRIMARY CARE. Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust PSYCHIATRIC MANAGEMENT IN PRIMARY CARE Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust Areas to cover Mood Disorders Anxiety Disorders Miscellaneous Conditions

More information

Psychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan

Psychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan Psychopharmacology in the Emergency Room Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan Pretest 1. Appropriate target symptoms for emergency room medication treatment

More information

8/15/17. Managing Psychiatric Conditions in Primary Care Beyond the Basics. Speaker s Biography. Situation

8/15/17. Managing Psychiatric Conditions in Primary Care Beyond the Basics. Speaker s Biography. Situation Managing Psychiatric Conditions in Primary Care Beyond the Basics Source: US National Library of Medicine, Images from the History of Medicine Luis Berrios, DNP, MHA, ANP, PMHNP Internal Medicine & Primary

More information